C12Y 301/27005
Pancreatic ribonuclease
Official title: Pancreatic ribonuclease (3.1.27.5)
C12Y301/27005 (Pancreatic ribonuclease) appears on 68 US grants and 119 published applications in this corpus.
Search patents in C12Y- Granted patents
- 68
- Published applications
- 119
- Assignees
- 45
- Inventors
- 118
- Latest grant
- 30 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 1 |
| 2003 | 0 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 1 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 0 | 3 |
| 2010 | 0 | 3 |
| 2011 | 3 | 2 |
| 2012 | 3 | 7 |
| 2013 | 2 | 8 |
| 2014 | 8 | 11 |
| 2015 | 3 | 9 |
| 2016 | 3 | 8 |
| 2017 | 6 | 9 |
| 2018 | 3 | 4 |
| 2019 | 2 | 7 |
| 2020 | 1 | 3 |
| 2021 | 5 | 6 |
| 2022 | 5 | 9 |
| 2023 | 3 | 7 |
| 2024 | 5 | 5 |
| 2025 | 7 | 6 |
| 2026 | 0 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Polynucleotides encoding APOA-1 fusion polypeptides30 Dec 2025US 12,509,501 B2Theripion, Inc.
- Therapeutic nuclease compositions and methods7 Oct 2025US 12,435,322 B2University of Washington
- Composition and method for treating or prophylaxis of coronavirus and cancers1 Jul 2025US 12,343,322 B2Betahealth LLC
- Composition and methods for treatment or prophylaxis of coronavirus and cancers24 Jun 2025US 12,336,975 B2Betahealth LLC
- Therapeutic nuclease compositions and methods24 Jun 2025US 12,338,466 B2University of Washington
- Assay of rna poly(a) tail length27 Aug 2026US 2026/0250762 A1Cellscript, LLC
- Methods for treating acute coronary syndrome using apoa-1 fusion proteins5 Mar 2026US 2026/0062460 A1Theripion, Inc.
- Therapeutic Nuclease Compositions and Methods12 Feb 2026US 2026/0043012 A1University of Washington
- Therapeutic nuclease compositions and methods5 Feb 2026US 2026/0035680 A1University of Washington
- Ribonucleases for treating viral infections6 Nov 2025US 2025/0339502 A1Orgenesis Inc.
Most cited
By later US patents
- Modulated release from biocompatible polymers263US 5,656,297 AAlkermes Controlled Therapeutics, Inc. · 1997
- Formulation of a reconstituted protein, and method and kit for the production thereof234US 5,580,856 A1996
- Modulated release from biocompatible polymers226US 5,912,015 AAlkermes Controlled Therapeutics, Inc. · 1999
- Glycopegylation methods and proteins/peptides produced by the methods57US 8,063,015 B2Novo Nordisk A/S · 2011
- Cytotoxic ribonuclease variants34US 7,416,875 B2Wisconsin Alumni Research Foundation · 2008